RTTNews BiotechCodex · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 22:56:58·⟳ 抓取 23:01:07 +4m09s·⚡ 决策 08-26 23:06:14 +5m07s·61.9 天前
BridgeBio启动ASCEND-ATTR研究首例给药，验证Acoramidis长期疾病逆转潜力
这是BridgeBio自有已获批药物Acoramidis的上市后长期研究进展，早于本条的公司Q2更新已写明ASCEND-ATTR已启动；首例给药本身不改变短期收入、审批状态或竞争格局，且缺少可执行报价与先例工具校验，不能形成正期望交易。
📄 原文RTTNews Biotech↗ 原文
BridgeBio Doses First Participation In ASCENT-ATTR Study
BridgeBio Pharma, Inc. (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study de…
不做 BridgeBio Pharma（BBIO.US）
不做BridgeBio Pharma（BBIO.US）：首例给药是长期上市后研究的程序性进展，项目启动已在8月10日披露，今日未新增疗效读出、审批变化、收入指引或可量化商业增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews转述的核心事实来自BridgeBio 2026年8月26日GlobeNewswire稿：ASCEND-ATTR首例给药，研究Acoramidis是否长期改善ATTR-CM心脏结构与淀粉样负荷。该研究有助于长期产品差异化叙事，但Acoramidis已经商业化，BridgeBio在2026年8月10日Q2更新中已披露ASCEND-ATTR启动，当前新增事实更像程序性进展而非收入或监管拐点，因此回避。
消息传播链
- BridgeBio发布官方通稿，宣布ASCEND-ATTR首例受试者给药并说明研究设计。市场反应:RTTNews正文称BBIO约80.24美元、跌0.20%，未见明显即时正向重定价。
- 财经媒体快速转载同一官方通稿，无新增金额、疗效数据或监管结论。
- 本次信号来源RTTNews转述同一事件，较官方稿晚约3小时26分钟。市场反应:正文显示BBIO盘中小跌。
关键理由
- Acoramidis长期若证明疾病逆转，可能强化ATTR-CM商业定位和医生采用逻辑。
- 但本次只是3b/4期长期研究首例给药，36个月主要终点决定短期业绩弹性的时点很远。
- 量级句：Acoramidis已商业化，当前事件未新增可触达患者数、价格、渗透率或收入指引，无法估算本次首例给药对BridgeBio收入/利润/市值的新增占比。
主要风险
- Q2更新已披露ASCEND-ATTR启动，今日首例给药的预期差偏小。
- 若后续ESC 2026数据强于预期，真正可交易催化更可能来自数据读出而不是本次给药启动。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-10 · 影响 weakens
公司Q2材料已写明ASCEND-ATTR已启动，削弱今日首例给药的新鲜度和预期差。
检索:BridgeBio Q2 2026 ASCEND-ATTR initiated acoramidis 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
公司已预告ESC 2026将发布更多Acoramidis数据，市场焦点可能在即将披露的数据而非本次研究给药启动。
检索:BridgeBio acoramidis ESC 2026 data August 24 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件新增性弱，促使最终不做BBIO。
方向:未形成可用于下单的高相似先例结论。
涨幅量级:无法用高相似、锚点干净的上市后首例给药先例校准短线幅度。
形态:上市后研究启动通常更接近长期叙事补强，若无同步疗效读出或指引变化，短线容易反应有限。
原文全文
展开原文 · 2,016 字
BridgeBio Pharma, Inc. (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to evaluate the long-term effects of Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The trial builds on earlier findings from the ATTRibute-CM CMR substudy, which suggested Acoramidis may not only slow disease progression but also improve cardiac structure and function, with evidence of amyloid regression in some patients.
Acoramidis is a selective, orally administered small molecules that stabilizes transthyretin (TTR) with near-complete (=90%) effectiveness. By preventing destabilization of the protein, the therapy may allow the body's natural clearance mechanisms to reduce amyloid deposits, enabling cardiac remodeling and functional recovery.
ASCENT-ATTR is a single-arm, open-label study enrolling about 150 participants with ATTR-CM. Patients will undergo annual cardiovascular magnetic resonance imaging and echocardiography over 36 months. The primary endpoint is improvement in left ventricular systolic function at Month 36, with secondary measures including cardiac structure, amyloid burden, biomarkers, and imaging assessments at Month 12 and 24.
ATTR-CM is a progressive and often fatal condition caused by amyloid deposits in the heart muscle. Current therapies aim to slow progression, but BridgeBio's program is designed to test whether long-term Acoramidis treatment can actively reverse disease damage and restore heart health.
BBIO has traded between $48.78 and $93.42 over the past year. The stock is currently trading at $80.24, down 0.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
The trial builds on earlier findings from the ATTRibute-CM CMR substudy, which suggested Acoramidis may not only slow disease progression but also improve cardiac structure and function, with evidence of amyloid regression in some patients.
Acoramidis is a selective, orally administered small molecules that stabilizes transthyretin (TTR) with near-complete (=90%) effectiveness. By preventing destabilization of the protein, the therapy may allow the body's natural clearance mechanisms to reduce amyloid deposits, enabling cardiac remodeling and functional recovery.
ASCENT-ATTR is a single-arm, open-label study enrolling about 150 participants with ATTR-CM. Patients will undergo annual cardiovascular magnetic resonance imaging and echocardiography over 36 months. The primary endpoint is improvement in left ventricular systolic function at Month 36, with secondary measures including cardiac structure, amyloid burden, biomarkers, and imaging assessments at Month 12 and 24.
ATTR-CM is a progressive and often fatal condition caused by amyloid deposits in the heart muscle. Current therapies aim to slow progression, but BridgeBio's program is designed to test whether long-term Acoramidis treatment can actively reverse disease damage and restore heart health.
BBIO has traded between $48.78 and $93.42 over the past year. The stock is currently trading at $80.24, down 0.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。